v3.25.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following is a summary of awards outstanding as of June 30, 2025 and 2024, which are not included in the computation of basic and diluted weighted average shares:
Three and six months ended
June 30,
20252024
Stock options (excluding exercisable penny stock options)8,831,326 5,993,356 
Restricted stock units283,411 283,411 
Warrants5,827,031 5,152,397 
Total14,941,768 11,429,164 
Schedule of Segment Reporting Information, by Segment In addition to the significant expense categories included within the total net loss presented on the Company's Statements of Operations, the following table sets forth significant segment expenses:
(in thousands)Three months ended June 30,Six months ended June 30,
2025202420252024
Employee expenses$2,833 $2,324 $5,872 $4,882 
Research and Development (excluding employee expenses):
Consulting and professional fees452 886 868 1,535 
Clinical study expenses7 417 11 658 
Product development647 363 1,356 559 
Other*335 189 638 470 
Total Research and development expense$1,441 $1,855 $2,873 $3,222 
General and administrative expense (excluding employee expenses):
General and administrative expenses592 757 1,325 1,531 
Commercialization readiness expenses171 154 468 239 
Total General and administrative expense763 911 1,793 1,770 
Total operating expenses$5,037 $5,090 $10,538 $9,874 

* Other primarily includes patent, and testing for three and six months ended June 30, 2025 and 2024.